Use of the QuantiFERON Monitor Assay to Predict Clinical Outcomes in Solid Organ and Hematopoietic Cell Transplant Recipients: A Scoping Review
Transplant Infectious Disease · 2025-07 · 27 (4)
DOI: 10.1111/tid.70074 ↗Kurz gefasst
Scoping Review in der Zeitschrift Transplant Infectious Disease, online erschienen am 01.07.2025. Verfasst von Bradley J Gardiner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Alfred Health and School of Translational Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Organ Transplantation, Interferon-gamma Release Tests, Graft Rejection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
QuantiFERON Monitor (QFM) is an interferon‐gamma release assay designed to provide a global measure of innate and adaptive cell‐mediated immune function. We performed a scoping review to explore published evidence on the ability of QFM to predict clinical outcomes in solid organ transplant (SOT) and allogeneic hematopoietic cell transplant (HCT) recipients.
Methods
A literature search was conducted using Embase, Cochrane, and PubMed databases and included studies reporting QFM values and the incidence of infection and/or organ rejection or graft‐versus‐host disease (GvHD).
Results
Thirteen publications (9 SOT, 4 HCT) were included. Among SOT studies, infection ( n = 8), rejection ( n = 3), mortality ( n = 2), and immunosuppression regimens ( n = 7) were assessed as outcomes; low QFM values were associated with increased infection risk in 7/8 studies. Correlations were also identified between immunosuppression regimens and QFM results in 6/7 studies. No clear relationships between QFM values and rejection or mortality could be determined, possibly due to the low number of events reported. Infection ( n = 4), GvHD ( n = 3), and mortality ( n = 1) were assessed in the HCT studies, with 3/4 reporting an association between low QFM values and infection. There was a high degree of heterogeneity in the transplant populations, outcome measures and definitions, QFM thresholds, and timing of sample collection.
Conclusions
The available data suggest that QFM may be able to identify overly immunosuppressed individuals at higher risk of infection; additional studies are needed to further evaluate its predictive utility in transplant and other settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Alfred Health and School of Translational Medicine, Monash University, Melbourne, Australia.
- Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- QIAGEN Manchester Ltd, Manchester, UK.
- QIAGEN S.r.l., Milan, Italy.
- Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Camille N Kotton
Zitieren
APA
Gardiner, B. J., Chemaly, R. F., Nikolayevskyy, V., Alagna, R., Manissero, D., & Kotton, C. N. (2025). Use of the QuantiFERON Monitor Assay to Predict Clinical Outcomes in Solid Organ and Hematopoietic Cell Transplant Recipients: A Scoping Review. Transplant Infectious Disease, 27(4). https://doi.org/10.1111/tid.70074
Vancouver
Gardiner BJ, Chemaly RF, Nikolayevskyy V, Alagna R, Manissero D, Kotton CN. Use of the QuantiFERON Monitor Assay to Predict Clinical Outcomes in Solid Organ and Hematopoietic Cell Transplant Recipients: A Scoping Review. Transplant Infectious Disease. 2025;27(4). doi:10.1111/tid.70074
BibTeX
@article{Gardiner2025,
author = {Gardiner, Bradley J and Chemaly, Roy F and Nikolayevskyy, Vladyslav and Alagna, Riccardo and Manissero, Davide and Kotton, Camille N},
title = {Use of the QuantiFERON Monitor Assay to Predict Clinical Outcomes in Solid Organ and Hematopoietic Cell Transplant Recipients: A Scoping Review},
journal = {Transplant Infectious Disease},
year = {2025},
volume = {27},
number = {4},
doi = {10.1111/tid.70074}
}
EUVIMED